Spots Global Cancer Trial Database for A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
Official Title: A Non-Interventional Multinational Study to Assess PD-L1 Expression in Cytological Versus Histological Non-Small Cell or Small Cell Lung Cancer Specimens
Study ID: NCT03092739
Study Description
Brief Summary: The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci, Praha 2, , Czechia
Universitätsklinikum Göttingen, Institut für Pathologie, Göttingen, , Germany
Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc, Warszawa, , Poland
Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Anatomía Patológica, A Coruña, LA Coruña, Spain
Hospital Universitario La Paz; Servicio de Anatomia Patologica, Madrid, , Spain
HOSPITAL DE MADRID NORTE SANCHINARRO- C. INTEGRAL ONC. CLARA CAMPAL; Servicio Anatomia Patologica, Madrid, , Spain
Universitätsspital Basel; Pathologie, Basel, , Switzerland
Aberdeen Royal Infirmary, Aberdeen, , United Kingdom
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
